HC Wainwright resumed coverage on Abeona Therapeutics with a new price target
$ABEO
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright resumed coverage of Abeona Therapeutics with a rating of Buy and set a new price target of $8.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $19.00 | Outperform | Oppenheimer |
| 3/5/2025 | $16.00 | Outperform | Oppenheimer |
| 7/3/2024 | $15.00 | Buy | H.C. Wainwright |
| 5/30/2024 | $21.00 | Buy | Stifel |
| 11/30/2021 | $5.00 → $1.00 | Outperform → Market Perform | SVB Leerink |
| 11/29/2021 | $5.00 → $4.00 | Buy | HC Wainwright & Co. |
| 7/19/2021 | $8.00 → $5.00 | Buy | HC Wainwright & Co. |
- First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with broad market access provide foundation for sustainable commercial success - - $207.5M in cash, cash equivalents, restricted cash and short-term investments as of September 30, 2025 expected to fund operations for over two years - CLEVELAND, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results and business highlights for the third quarter of 2025 and shared recent operational progress. "We are scaling the ZEVASKYN launch to meet patient needs
CLEVELAND, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it will host a conference call on Wednesday, November 12, 2025 at 8:30 a.m. ET to discuss its third quarter 2025 financial results and corporate progress. The conference call will be available via phone and webcast. To access the call, dial 877-545-0523 (U.S. toll-free) or 973-528-0016 (international) and Entry Code: 922481 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona's website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will be available
CLEVELAND, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On October 31, 2025, the Compensation Committee of Abeona's Board of Directors granted restricted stock equity awards as a material inducement to employment to eleven individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 71,035 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that
10-Q - ABEONA THERAPEUTICS INC. (0000318306) (Filer)
8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)
SCHEDULE 13G - ABEONA THERAPEUTICS INC. (0000318306) (Subject)
4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
Oppenheimer resumed coverage of Abeona Therapeutics with a rating of Outperform and set a new price target of $19.00
Oppenheimer initiated coverage of Abeona Therapeutics with a rating of Outperform and set a new price target of $16.00
H.C. Wainwright initiated coverage of Abeona Therapeutics with a rating of Buy and set a new price target of $15.00
CLEVELAND, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the appointment of James A. Gow, MD, MBA, MS, MHCM, as the Senior Vice President, Head of Clinical Development & Medical Affairs, effective immediately. "We are thrilled to welcome Dr. Gow to our executive team," said Vish Seshadri, Chief Executive Officer of Abeona. "James has a proven track record of leading novel gene therapy programs for inherited retinal diseases. His addition to our team will be invaluable as we advance our pipeline and deliver transformative treatments to patients."
CLEVELAND, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Bernhardt G. Zeiher, MD, FCCP, FACP, and Eric Crombez, MD as new independent members to its Board of Directors. Dr. Zeiher brings more than 20 years of drug development experience where, in various roles, he oversaw the approval of 15 new treatments that addressed unmet needs in serious diseases with few to no treatment options. Dr. Crombez currently serves as Chief Medical Officer of Ultragenyx Pharmaceutical Inc. and brings extensive expertise in the development and execution of clinical development programs for rare genetic disorders. Michael Amoroso, Chairman of Abeon
CLEVELAND, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Madhav Vasanthavada, Ph.D., M.B.A. to the role of Chief Commercial Officer (CCO) and Head of Business Development (BD), effective immediately. In this capacity, in addition to his current BD responsibilities, Dr. Vasanthavada will oversee all aspects of commercial strategy, planning and operations as Abeona prepares for a potential launch of EB-101, its investigational, genetically engineered autologous cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). Dr. Vasanthavada is a seasoned commercial executive bringing over 20 years of experience with leadershi
- First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with broad market access provide foundation for sustainable commercial success - - $207.5M in cash, cash equivalents, restricted cash and short-term investments as of September 30, 2025 expected to fund operations for over two years - CLEVELAND, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results and business highlights for the third quarter of 2025 and shared recent operational progress. "We are scaling the ZEVASKYN launch to meet patient needs
CLEVELAND, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it will host a conference call on Wednesday, November 12, 2025 at 8:30 a.m. ET to discuss its third quarter 2025 financial results and corporate progress. The conference call will be available via phone and webcast. To access the call, dial 877-545-0523 (U.S. toll-free) or 973-528-0016 (international) and Entry Code: 922481 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona's website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will be available
- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) - - U.S. launch on track and first ZEVASKYN patient treatment expected in 3Q 2025, momentum building with strong patient interest at qualified treatment centers and referrals, positive insurance coverage established with multiple national and regional payers - - $226M in cash, cash equivalents, restricted cash and short-term investments as of June 30, 2025, expected to fund operations for over two years before accounting for anticipated ZEVASKYN revenue beginn
SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)
SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)
SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)